创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

LI Qinzhi, CHENG Yanxia, LI Bo, ZHANG Jinsong. Research Progress of Radionuclide Labeled Nanoliposome in Tumor Diagnosis and TreatmentJ. Progress in Pharmaceutical Sciences, 2026, 50(1): 21-26. DOI: 10.20053/j.issn1001-5094.20250053
Citation: LI Qinzhi, CHENG Yanxia, LI Bo, ZHANG Jinsong. Research Progress of Radionuclide Labeled Nanoliposome in Tumor Diagnosis and TreatmentJ. Progress in Pharmaceutical Sciences, 2026, 50(1): 21-26. DOI: 10.20053/j.issn1001-5094.20250053

Research Progress of Radionuclide Labeled Nanoliposome in Tumor Diagnosis and Treatment

  • Based on the characteristics of nanoliposome, such as good biocompatibility, surface modifiability, selectivity and targeting, etc., the combination of radionuclide and nanoliposome can accomplish the objective of reducing adverse reaction of radiopharmaceutical, increasing the therapeutic efficiency and targeted concentration. Recently in the field of nuclear medicine and nuclear pharmacy, more and more nuclear nanomedicines have been applied in the clinical researches, showing good development prospects. For the radiolabeled nanoliposome, the research progress of labeling methods, targeting, clinical application, etc., and future application prospects are analyzed and reviewed, aiming to provide a new possibility for the targeted diagnosis and treatment of tumors.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return